University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

Benzene (CAS 71-43-2)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
ezy nas orc ski sto vsc ezy nas orc sto vsc ezy hag hmo lun pre ezy hmo lun mgl ova 169m 77.5m,v

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   ezy = ear/Zymbal’s gland. hag = harderian gland. hmo = hematopoietic system. lun = lung. mgl = mammary gland. nas = nasal cavity (includes tissues of the nose, nasal turbinates, paranasal sinuses and trachea). orc = oral cavity (includes tissues of the mouth, oropharynx, pharynx, and larynx). ova = ovary. pre = preputial gland. ski = skin. sto = stomach. vsc = vascular system. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Benzene: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

BENZENE 71-43-2 615 M f b6c gav 24m24 TR289 : 0 17.7mg 35.4mg 70.7mg MXB MXB 23.7mg * P<.0005 14.9mg 50.7mg 17/50 28/50 41/50 42/50 lun:a/a,a/c; mgl:can,cas,sqc; mul:mlh,mlm,mlp, mlu,mno; ova:gct,lut,mtb,pcy,tua; spl:mlm,mlu,mno; ute:mlh; zym:sqc. M MXB MXB 24.6mg * P<.0005 15.3mg 54.6mg 17/50 28/50 40/50 41/50 lun:a/a,a/c; mgl:can,cas,sqc; mul:mlh,mlm,mlp, mlu,mno; ova:gct,mtb; spl:mlm,mlu,mno; ute:mlh; zym:sqc. C liv hpa 38.1mg Z P<.008 15.9mg 880.mg 1/50 8/50 (5/50 4/50) S liv MXA 53.6mg Z P<.009 26.3mg 2.27gm 4/50 12/50 13/50 (7/50) liv:hpa,hpc. S ova mtb 66.5mg Z P<.0005 c 34.6mg 156.mg 0/50 1/50 12/50 (7/50) lun MXA 83.6mg * P<.002 c 44.0mg 354.mg 4/50 5/50 10/50 13/50 lun:a/a,a/c. lun a/c 117.mg * P<.0005 c 63.4mg 390.mg 0/50 3/50 6/50 6/50 ova MXB 119.mg * P<.0005 63.8mg 374.mg 0/50 2/50 7/50 5/50 ova:lut,pcy,tua. P mgl MXA 132.mg * P<.0005 c 73.1mg 294.mg 0/50 2/50 5/50 10/50 mgl:can,sqc. ova MXA 146.mg * P<.002 74.0mg 571.mg 1/50 1/50 6/50 8/50 ova:gcc,gct. S ova gct 157.mg * P<.002 c 77.1mg 793.mg 1/50 1/50 6/50 7/50 ova tua h 295.mg * P<.006 p 120.mg 3.25gm 0/50 0/50 3/50 3/50 mgl cas 382.mg * P<.005 c 143.mg 3.12gm 0/50 0/50 1/50 4/50 hag can 509.mg * P<.006 174.mg 5.94gm 0/50 0/50 0/50 4/50 S MXA MXA 79.1mg * P<.04 34.3mg n.s.s. 15/50 25/50 26/50 22/50 mul:lkn,mlh,mlm,mlp,mlu,mno,ule; spl:mlm,mlu, mno; ute:mlh. S MXA MXA 94.2mg * P<.07 c 37.2mg n.s.s. 15/50 24/50 24/50 20/50 mul:mlh,mlm,mlp,mlu,mno; spl:mlm,mlu,mno; ute: mlh. hag MXA 128.mg * P<.02 57.4mg n.s.s. 5/50 6/50 10/50 10/50 hag:adn,can. S lun a/a 169.mg * P<.02 c 72.8mg n.s.s. 4/50 2/50 5/50 9/50 MXA sqp 173.mg * P<.02 77.4mg n.s.s. 1/50 3/50 6/50 5/50 cst:sqp; sto:sqp. S ova lut h 245.mg * P<.05 p 106.mg n.s.s. 0/50 2/50 3/50 2/50 zym sqc 421.mg * P<.02 c 146.mg n.s.s. 0/50 0/50 1/50 3/50 ova pcy h 574.mg * P<.08 p 174.mg n.s.s. 0/50 0/50 2/50 1/50 TBA MXB 30.4mg * P<.002 16.1mg 158.mg 36/50 40/50 48/50 48/50 liv MXB 53.6mg Z P<.009 26.3mg 2.27gm 4/50 12/50 13/50 (7/50) liv:hpa,hpc,nnd. lun MXB 83.6mg * P<.002 44.0mg 354.mg 4/50 5/50 10/50 13/50 lun:a/a,a/c. 616 M m b6c gav 24m24 TR289 : 0 17.7mg 35.4mg 71.4mg MXB MXB 15.1mg * P<.0005 10.1mg 26.0mg 13/50 28/50 35/50 42/50 hag:adn; lun:a/a,a/c; mul:mlh,mlm,mlp,mlu,mno; pre:sqc; spl:mlh,mno; zym:sqc. C pre MXA 21.8mg Z P<.0005 15.1mg 32.6mg 0/50 5/50 19/50 31/50 pre:can,sqc. S pre sqc 25.5mg Z P<.0005 c 17.3mg 38.9mg 0/50 3/50 18/50 28/50 hag MXA 39.5mg * P<.0005 24.5mg 79.0mg 1/50 10/50 13/50 14/50 hag:adn,can. S hag adn 40.7mg * P<.0005 c 25.7mg 73.0mg 0/50 9/50 13/50 11/50 lun MXA 42.5mg * P<.0005 c 24.1mg 121.mg 10/50 16/50 19/50 21/50 lun:a/a,a/c. MXA MXA 50.9mg * P<.0005 28.4mg 141.mg 4/50 10/50 10/50 15/50 mul:lkn,mlh,mlm,mlp,mlu,mno; spl:mlh,mno. S MXA MXA 51.8mg * P<.0005 c 28.8mg 141.mg 4/50 9/50 9/50 15/50 mul:mlh,mlm,mlp,mlu,mno; spl:mlh,mno. zym sqc 56.3mg Z P<.0005 c 33.8mg 101.mg 0/50 1/50 4/50 21/50 lun a/c 59.5mg * P<.0005 c 31.8mg 214.mg 5/50 11/50 12/50 14/50 lun a/a 103.mg * P<.004 48.7mg 900.mg 6/50 6/50 8/50 12/50 S adr phe 116.mg Z P<.01 47.9mg 14.1gm 1/50 1/50 7/50 (1/50) S ski MXA 262.mg * P<.004 94.4mg 1.96gm 0/50 0/50 2/50 3/50 ski:sqc,squ. S MXA mlh 269.mg * P<.005 c 98.0mg 2.24gm 0/50 0/50 3/50 3/50 mul:mlh; spl:mlh. MXA MXA 169.mg * P<.02 66.5mg n.s.s. 2/50 2/50 3/50 5/50 cst:sqc,sqp; sto:sqc. S cst sqp 222.mg * P<.03 80.3mg n.s.s. 2/50 1/50 2/50 5/50 S TBA MXB 17.1mg * P<.0005 10.4mg 38.6mg 33/50 40/50 48/50 46/50 liv MXB 102.mg * P<.2 35.1mg n.s.s. 15/50 17/50 22/50 11/50 liv:hpa,hpc,nnd. lun MXB 42.5mg * P<.0005 24.1mg 121.mg 10/50 16/50 19/50 21/50 lun:a/a,a/c. 617 M m aks inh 72w72 1048 0 83.7mg Snyder;txap,54,323-331;1980 --- mly e 114.mg P<.3 - 32.4mg n.s.s. 24/50 29/49 618 M m c56 inh 69w69 1048 0 251.mg thm lym h 466.mg P<.004 + 190.mg 2.81gm 0/40 6/40 --- mix h 441.mg P<.04 + 167.mg n.s.s. 2/40 8/40 --- lcl h 681.mg P<.2 + 212.mg n.s.s. 2/40 6/40 619 M f swi gav 18m24 BT908 0 241.mg Maltoni;anya,534,412-426;1988 mam car 279.mg P<.0005 + 154.mg 655.mg 2/40 19/40 lun mix 453.mg P<.004 + 214.mg 3.43gm 4/40 15/40 lun ata 1.02gm P<.004 414.mg 6.13gm 0/40 6/40 lun ade 1.10gm P<.2 362.mg n.s.s. 4/40 9/40 zym car 6.52gm P<.3 + 1.06gm n.s.s. 0/40 1/40 liv hpt no dre P=1. 1.99gm n.s.s. 0/40 0/40 tba mix 150.mg P<.0005 77.1mg 523.mg 16/40 32/40 tba mal 187.mg P<.0005 + 99.1mg 589.mg 11/40 28/40 620 M m swi gav 18m24 BT908 0 241.mg lun mix 382.mg P<.0005 + 193.mg 1.39gm 3/40 16/40 lun ade 811.mg P<.02 330.mg n.s.s. 2/40 9/40 lun ata 1.20gm P<.04 436.mg n.s.s. 1/40 6/40 zym car 1.57gm P<.02 + 541.mg n.s.s. 0/40 4/40 liv hpt 6.19gm P<.7 756.mg n.s.s. 2/40 3/40 lun adc 6.52gm P<.3 1.06gm n.s.s. 0/40 1/40 tba mix 370.mg P<.05 149.mg n.s.s. 15/40 24/40 tba mal 939.mg P<.3 + 279.mg n.s.s. 9/40 14/40 621 R f f34 gav 24m24 TR289 : 0 17.7mg 35.4mg 70.7mg MXB MXB 55.1mg * P<.0005 37.2mg 96.2mg 1/50 10/50 16/50 21/50 cst:sqp; lpp:sqp; pal:sqc,sqp; ton:sqc,sqp; zym: can. C zym MXA 97.9mg * P<.0005 60.8mg 179.mg 0/50 5/50 6/50 15/50 zym:adn,can. S zym can 109.mg * P<.0005 c 66.3mg 207.mg 0/50 5/50 5/50 14/50 MXA MXA 113.mg * P<.0005 c 65.7mg 333.mg 1/50 5/50 12/50 9/50 cst:sqp; lpp:sqp; pal:sqc,sqp; ton:sqc,sqp. ute esp 158.mg * P<.008 73.3mg 4.18gm 7/50 7/50 7/50 14/50 S MXA sqp 186.mg * P<.01 c 90.9mg 13.1gm 1/50 4/50 8/50 5/50 cst:sqp; lpp:sqp; pal:sqp; ton:sqp. MXA sqc 290.mg * P<.002 c 141.mg 1.14gm 0/50 1/50 4/50 5/50 pal:sqc; ton:sqc. ton MXA 295.mg * P<.003 c 143.mg 1.56gm 0/50 1/50 5/50 4/50 ton:sqc,sqp. ton sqc 368.mg * P<.003 c 166.mg 1.76gm 0/50 0/50 4/50 4/50 pal MXA 288.mg * P<.06 c 118.mg n.s.s. 1/50 4/50 5/50 4/50 pal:sqc,sqp. MXA MXA 364.mg * P<.04 157.mg n.s.s. 0/50 2/50 3/50 2/50 cvu:adq; utm:acn,can. S TBA MXB 46.7mg * P<.006 23.3mg 567.mg 38/50 39/50 41/50 42/50 liv MXB no dre P=1. 238.mg n.s.s. 0/50 3/50 1/50 0/50 liv:hpa,hpc,nnd. 622 R m f34 gav 24m24 TR289 : 0 35.4mg 70.7mg 142.mg MXB MXB 51.1mg * P<.0005 35.9mg 83.8mg 3/50 21/50 27/50 37/50 lpp:sqc,sqp; pal:sqc,sqp; ski:sqc,sqp; ton:sqc, sqp; zym:can. C MXA MXA 91.5mg * P<.0005 c 59.4mg 174.mg 1/50 9/50 16/50 19/50 lpp:sqc,sqp; pal:sqc,sqp; ton:sqc,sqp. MXA sqp 140.mg * P<.0005 c 84.2mg 334.mg 1/50 6/50 11/50 13/50 lpp:sqp; pal:sqp; ton:sqp. zym MXA 155.mg * P<.0005 92.8mg 363.mg 2/50 7/50 10/50 18/50 zym:adn,can. S zym can 166.mg * P<.0005 c 98.3mg 401.mg 2/50 6/50 10/50 17/50 ski MXA 181.mg * P<.0005 102.mg 544.mg 1/50 7/50 5/50 12/50 ski:adq,sqc,sqp,ulc. S ski MXA 191.mg * P<.0005 105.mg 656.mg 1/50 7/50 5/50 11/50 ski:adq,sqc,sqp. S lpp MXA 220.mg * P<.0005 c 120.mg 519.mg 0/50 2/50 5/50 8/50 lpp:sqc,sqp. pal MXA 243.mg * P<.0005 c 135.mg 635.mg 0/50 4/50 5/50 9/50 pal:sqc,sqp. pal sqp 250.mg * P<.0005 c 138.mg 668.mg 0/50 4/50 4/50 9/50 ski sqc 260.mg * P<.0005 c 143.mg 859.mg 0/50 5/50 3/50 8/50 lpp sqp 284.mg * P<.002 c 145.mg 986.mg 0/50 2/50 5/50 5/50 MXA sqc 295.mg * P<.0005 c 156.mg 977.mg 0/50 3/50 5/50 7/50 lpp:sqc; pal:sqc; ton:sqc. ski sqp 427.mg * P<.003 c 192.mg 2.56gm 0/50 2/50 1/50 5/50 ton MXA 382.mg * P<.02 c 173.mg n.s.s. 1/50 3/50 6/50 6/50 ton:sqc,sqp. ton sqc 430.mg * P<.02 c 206.mg n.s.s. 0/50 3/50 4/50 4/50 lpp sqc 1.15gm * P<.02 c 349.mg n.s.s. 0/50 0/50 0/50 3/50 TBA MXB 68.1mg * P<.006 33.7mg 799.mg 39/50 44/50 45/50 47/50 liv MXB 1.91gm * P<.7 261.mg n.s.s. 2/50 2/50 5/50 1/50 liv:hpa,hpc,nnd. 623 R f sda inh 24m35 BT4004 0 53.4mg Maltoni;ajim,7,415-446;1985 mgl mal egv 907.mg P<.1 291.mg n.s.s. 2/60 6/54 orc car egv 2.02gm P<.09 496.mg n.s.s. 0/60 2/54 zym car egv 1.89gm P<.3 433.mg n.s.s. 1/60 3/54 liv hpt egv 4.07gm P<.3 663.mg n.s.s. 0/60 1/54 nas car egv 4.07gm P<.3 663.mg n.s.s. 0/60 1/54 tba car egv 947.mg P<.07 314.mg n.s.s. 1/60 5/54 tba mal egv 553.mg P<.2 + 181.mg n.s.s. 9/60 14/54 624 R f sda gav 12m33 BT901 0 11.6mg 58.0mg Maltoni;ajim,7,415-446;1985/1979 zym car ej 222.mg * P<.0005 + 108.mg 716.mg 0/30 2/28 8/28 orc car ej 945.mg * P<.04 + 232.mg n.s.s. 0/29 0/24 2/21 mgl mal ej 517.mg * P<.3 141.mg n.s.s. 4/30 4/28 7/28 liv hpt ej no dre P=1. 74.1mg n.s.s. 0/13 0/30 0/7 ski car ej no dre P=1. 117.mg n.s.s. 0/30 0/30 0/35 --- leu ej no dre P=1. 382.mg n.s.s. 1/30 2/30 1/29 tba mal ej 75.3mg * P<.0005 39.4mg 237.mg 7/30 10/28 21/29 625 R f sda gav 24m33 BT902 0 237.mg Maltoni;ajim,7,415-446;1985 orc car e 415.mg P<.0005 + 242.mg 794.mg 0/49 20/39 zym car e 585.mg P<.0005 + 324.mg 1.21gm 0/49 16/40 for cic e 787.mg P<.002 + 318.mg 3.25gm 0/24 6/19 liv hpt e 4.03gm P<.3 655.mg n.s.s. 0/15 1/14 liv ang e 7.91gm P<.2 + 1.29gm n.s.s. 0/35 1/27 nas car e 8.51gm P<.2 + 1.39gm n.s.s. 0/40 1/29 ski car e no dre P=1. 2.42gm n.s.s. 1/35 0/27 tba mal e 161.mg P<.0005 92.3mg 312.mg 10/49 35/40 tba car 248.mg P<.0005 152.mg 432.mg 0/50 28/40 626 R m sda gav 12m33 BT901 0 11.6mg 58.0mg Maltoni;ajim,7,415-446;1985/1979 --- leu ej 506.mg * P<.008 175.mg 8.25gm 0/22 0/23 4/24 liv hpt ej 3.09gm * P<.2 503.mg n.s.s. 0/30 0/30 1/35 sub ang ej 3.09gm * P<.2 503.mg n.s.s. 0/30 0/30 1/35 mgl mal ej no dre P=1. 84.1mg n.s.s. 0/22 0/22 0/22 orc car ej no dre P=1. 74.2mg n.s.s. 0/19 0/20 0/17 ski car ej no dre P=1. 117.mg n.s.s. 0/30 0/30 0/35 zym car ej no dre P=1. 84.1mg n.s.s. 0/22 0/22 0/22 tba mal ej 232.mg * P<.004 101.mg 1.63gm 1/22 1/23 8/24 627 R m sda gav 24m33 BT902 0 237.mg Maltoni;ajim,7,415-446;1985 orc car e 386.mg P<.0005 + 227.mg 727.mg 0/45 21/39 zym car e 501.mg P<.0005 + 280.mg 1.07gm 1/45 18/39 ski car e 904.mg P<.0005 + 424.mg 2.57gm 0/34 9/32 nas car e 3.53gm P<.05 + 1.07gm n.s.s. 0/35 3/37 liv ang e 4.48gm P<.09 + 1.10gm n.s.s. 0/32 2/31 for ivc e 6.12gm P<.2 + 996.mg n.s.s. 0/44 1/21 liv hpt e no dre P=1. 523.mg n.s.s. 3/15 3/15 tba mal e 131.mg P<.0005 70.6mg 260.mg 11/45 36/39 tba car 219.mg P<.0005 134.mg 382.mg 1/50 30/40 628 R m sda inh 98w98 518 0 50.4mg Snyder;jtxe,4,605-618;1978 liv tum no dre P=1. - 415.mg n.s.s. 0/27 0/45 tba tum no dre P=1. - 415.mg n.s.s. 0/27 0/45 629 R m sda inh 29m29 2305 0 16.7mg Snyder;ajim,5,429-434;1984 liv mix s 152.mg P<.02 52.6mg n.s.s. 0/40 4/40 zym car s 313.mg P<.1 76.9mg n.s.s. 0/40 2/40 --- grl s 634.mg P<.3 103.mg n.s.s. 0/40 1/40 mgl adc s 634.mg P<.3 103.mg n.s.s. 0/40 1/40 tba mix s 65.9mg P<.02 27.7mg n.s.s. 3/40 11/40 tba mal s 93.4mg P<.04 35.5mg n.s.s. 2/40 8/40 tba ben s 305.mg P<.3 67.3mg n.s.s. 1/40 3/40 630 R f wis gav 24m24 BT907 0 321.mg Maltoni;anya,534,412-426;1988 zym sqc 1.36gm P<.004 552.mg 8.18gm 0/40 6/40 orc sqc 2.09gm P<.02 722.mg n.s.s. 0/40 4/40 nas ulc 8.70gm P<.3 1.42gm n.s.s. 0/40 1/40 tba mal 482.mg P<.02 217.mg n.s.s. 10/40 21/40 tba mix no dre P=1. 408.mg n.s.s. 34/40 27/40 631 R m wis gav 24m24 BT907 0 321.mg zym sqc 1.14gm P<.002 494.mg 4.73gm 0/40 7/40 nas ulc 4.29gm P<.1 1.06gm n.s.s. 0/40 2/40 orc sqc 8.48gm P<.6 1.16gm n.s.s. 1/40 2/40 tba mal 523.mg P<.01 238.mg 26.9gm 8/40 19/40 tba mix no dre P=1. 490.mg n.s.s. 30/40 23/40

Mutagenicity in Salmonella: negative
SMILES Code for Benzene: C1=CC=CC=C1
InChI Code for Benzene: InChI=1/C6H6/c1-2-4-6-5-3-1/h1-6H
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for Benzene: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10